Proteomimetic polymer blocks mitochondrial damage, rescues Huntington’s neurons, and slows onset of neuropathology in vivo
Authors:
Open Access
- 1 November 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (44) , eado8307
Abstract
Recently, it has been shown that blocking the binding of valosin-containing protein (VCP) to mutant huntingtin (mtHtt) can prevent neuronal mitochondrial autophagy in Huntington’s disease (HD) models. Herein, we describe the development and efficacy of a protein-like polymer (PLP) for inhibiting this interaction in cellular and in vivo models of HD. PLPs exhibit bioactivity in HD mouse striatal cells by successfully inhibiting mitochondrial destruction. PLP is notably resilient to in vitro enzyme, serum, and liver microsome stability assays, which render analogous control oligopeptides ineffective. PLP demonstrates a 2000-fold increase in circulation half-life compared to peptides, exhibiting an elimination half-life of 152 hours. In vivo efficacy studies in HD transgenic mice (R6/2) confirm the superior bioactivity of PLP compared to free peptide through behavioral and neuropathological analyses. PLP functions by preventing pathologic VCP/mtHtt binding in HD animal models; exhibits enhanced efficacy over the parent, free peptide; and implicates the PLP as a platform with potential for translational central nervous system therapeutics.Keywords
This publication has 55 references indexed in Scilit:
- Interaction of Arginine-Rich Peptides with Membrane-Associated Proteoglycans Is Crucial for Induction of Actin Organization and MacropinocytosisBiochemistry, 2006
- Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide deliveryCurrent Opinion in Pharmacology, 2006
- Pathological consequences of VCP mutations on human striated muscleBrain, 2006
- The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategiesNeuroRX, 2005
- Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cellsHuman Molecular Genetics, 2000
- Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease miceProceedings of the National Academy of Sciences, 2000
- Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and ApplicationsChemical Reviews, 1999
- Transgenic mice expressing a Huntington’s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicityProceedings of the National Academy of Sciences, 1999
- Bioadhesive polymers in peptide drug deliveryBiomaterials, 1990
- HIV-1 tat trans-activation requires the loop sequence within tarNature, 1988